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Summary The aim of this study was to assess relationships between Bcl-2 expression, response to
chemotherapy and a number of pathological and biological tumour parameters in premenopausal, lymph
node-negative breast cancer patients. Expression of Bcl-2 was determined using immunohistochemistry on
paraffin-embedded sections in a series of 441 premenopausal, lymph node-negative breast cancers of patients
randomised to receive perioperative chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide) or no
perioperative chemotherapy. Immunohistochemistry of Bcl-2 was evaluated by scoring both staining intensity
(0-3) and number ofpositive cells (0-2). Using these scores tumours were grouped into categories 0-6. It was
found that 9.2% of the tumours were completely negative (0), 17.2% weakly (1+2), 41.6% moderately (3 +4)
and 31.9% strongly positive (5+6) for Bcl-2. A positive correlation was found between high Bcl-2 expression
and oestrogen (P<0.001) and progesterone receptor positivity (P<0.001) and low tumour grade (P<0.001),
whereas high Bcl-2 expression was negatively correlated with p53 (P<0.001) and c-erb-B-2 positivity
(P<0.001), high Ki-67 index (P<0.001), mitotic index (P<0.001) and large tumour size (P=0.006). Patients
with tumours expressing high levels of Bcl-2 (overall score 3-6) had a significantly better disease-free
(P=0.004) and overall (P=0.009) survival. However, in a multivariate model this association no longer
remained significant. There was a trend for an effect of adjuvant chemotherapy on disease-free survival both
for patients with Bcl-2-positive (HR-0.61, 95% CI 0.35-1.06, P=0.07) and negative (HR=0.55, 95% CI
0.27-1.12, P=0.09) breast tumours at a median follow-up of 49 months. The level of Bcl-2 expression does
not seem to predict response to perioperative chemotherapy in premenopausal, lymph node-negative breast
cancer patients. High levels of Bcl-2 are preferentially expressed in well-differentiated tumours and are
associated with favourable prognosis. However, Bcl-2 expression is not an independent prognostic factor in this
patient series.
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The product of the bcl-2 gene has been shown to protect cells
against cell death induced by a myriad of insults, including
most chemotherapeutic drugs (Reed, 1994). For this reason,
it has been hypothesised that bcl-2 overexpression may play a
role in resistance to chemotherapy, as has recently been
demonstrated for neuroblastomas (Castle et al., 1993) and
acute myeloid leukaemia (Campos et al., 1993).
Bcl-2 is present in mature lymphoid cell populations, in
long-lived post-mitotic cells (e.g. neurons), in complex
organised epithelia (e.g. skin, gastrointestinal mucosa) and
in glandular epithelium under hormonal and growth factor
control (e.g. thyroid, prostate, uterus and breast) (Hock-
enbery et al., 1991; Gompel et al., 1994).
The bct-2 gene is a member of a gene family, which
includes bcl-X (74% homology) (Boise et al., 1993) and bax
(21% homology) (Oltvai et al., 1993). Bcl-2 immunoreactivity
was demonstrated to be confined to the mitochondrial outer
circumference and the nuclear envelope and to a lesser degree
to the cell membrane (De Jong et al., 1994). The cellular
mechanism by which Bcl-2 protein functions has not yet been
elucidated, but recent data suggest that heterodimerisation
with Bax proteins is important (Yin et al., 1995).
Furthermore, it has recently been reported that bcl-2
expression is inhibited by the product of the p53 tumour-
suppressor gene (Haldar et al., 1994; Miyashita et al., 1994;
Selvakumaran et al., 1994), an important determinant in the
induction of apoptosis (Merritt et al., 1994; Lowe et al., 1993;
Zhu et al., 1994; Debbas and White, 1993).
Bcl-2 has been shown to be frequently expressed in breast
cancer. Leek et al. (1994) reported a strong correlation
between the presence of Bcl-2 (72/111 positives) and
oestrogen receptor (ER) positivity in a series of 111 breast
cancers; no relationship was found with lymph node status,
tumour size or differentiation type and an inverse relationship
with immunostaining of p53 and c-erbB-2 proteins respec-
tively. Similar findings were recently reported by Silvestrini et
al. (1994); in a series of 283 breast cancers from lymph node-
negative patients, the highest fraction of Bcl-2 positive cells
was found in small, ER-positive, slowly proliferating and
p53-negative tumours and a stronger association was seen
between Bcl-2 and p53 than between these variables and
proliferative activity. Bcl-2 predicted 6 year relapse-free and
overall survival, but its prognostic value seemed to mainly
depend on p53 expression. Bhargava et al. (1994) observed a
positive correlation between Bcl-2 and ER and progesterone
receptor (PgR) in a series of 41 breast cancers and Joensuu et
al. (1994) reported in a series of 174 patients a correlation
with lack of p53 expression, high histological grade, lack of
tumour necrosis, low cathepsin D expression and low S-phase
fraction, but not with primary tumour size or axillary node
status. A number of studies reported a significant positive
association between Bcl-2 positivity and increased overall
survival in node-positive breast cancer patients treated with
chemotherapy and/or hormone therapy (Gasparini et al.,
1995; Gee et al., 1994; Hellemans et al., 1995), whereas no
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association between Bcl-2 expression and prognosis could be
demonstrated in patients that did not receive adjuvant
therapy (Joensuu et al., 1994; Hellemans et al., 1995). Thus,
it has been suggested that Bcl-2 expression may be a useful
predictor for response to chemotherapy in breast cancer
patients.
In this study we evaluated the prognostic significance of
Bcl-2 in 441 lymph node-negative, premenopausal breast
cancer patients randomised to receive perioperative che-
motherapy [5-fluorouracil (F), doxorubicin (A), cyclopho-
sphamide (C); FAC, administered within 24 h after surgery]
vs no treatment. The presence of a control group of untreated
patients, allowed us to assess relationships between Bcl-2
expression and response to perioperative chemotherapy. In
addition, the correlations between Bcl-2 expression and a
number of previously analysed tumour parameters [e.g. p53,
Ki-67, ER, PgR and c-erbB-2 (Clahsen et al., 1994a)] were
assessed.
Materials and methods
Patients
All 441 premenopausal women with node-negative early
breast cancer were drawn from a large prospectively
randomised adjuvant trial (EORTC Trial 10854), comparing
surgery followed by perioperative chemotherapy vs surgery
alone. The eligibility criteria for this trial have been described
previously (Clahsen et al., 1994b). Follow-up for recurrent
disease was requested 6 months after surgery, 1 year after
surgery and yearly thereafter. Minimal requirements for
follow-up were physical examination, performance scale
assessment, chest radiograph, mammography, alkaline
phosphatase and lactate dehydrogenase measurements every
year post operatively, where bone scan was optional. At a
median follow-up period of 4.08 years (range 0.25-7.08),
overall and disease-free survival percentages (±s.d.) were 94
(± 1.3) and 82 (± 1.9) percent respectively.
Treatment
Local treatment consisted of either (modified) radical
mastectomy or tumourectomy plus radiation therapy, in
combination with axillary clearance. Patients were then
consecutively randomised to either receive one course of
600 mg m-2 F, 50 mg m-2 A and 600 mg m-2 C intrave-
nously, within 24 h after surgery, or no adjuvant chemother-
apy.
Detection of Bc1-2
Tissue sections fixed in formaldehyde or Bouin's solution
were deparaffinised, dehydrated and blocked for endogenous
peroxidase by rinsing in methanol containing 0.12%
hydrogen peroxide. Tissue sections were then rehydrated
and washed twice in distilled water. Subsequently, tissue
sections were heated in 0.01 M citrate buffer (pH 6.0) to
100°C for 20 min and cooled down to room temperature
within 2 h. After washing twice in distilled water and twice in
phosphate-buffered saline (PBS), sections were incubated
overnight with Bcl-2.124 monoclonal antibody (a generous
gift from Dr D Y Mason) diluted 1:100 in PBS containing
1% bovine serum albumin (BSA). Next, sections were washed
three times in PBS and incubated 1 h with rabbit anti-mouse
immunoglobulins (Dako, Glostrup, Denmark), diluted 1:200.
After washing three times in PBS, sections were incubated 1 h
with StreptABComplex/HRP (Dako), diluted 1:100. Staining
was developed with diaminobenzidine and hydrogen peroxide
and counterstained with haematoxylin. In all sections,
infiltrating lymphocytes used as an internal positive control,
stained strongly positive: tumours in which no positive
lymphocytes could be observed were omitted from the
series. Cytoplasmic staining of Bcl-2 was evaluated by two
observers' (H-JvS and JHvD) using light microscopy.
Detection of various prognosticfactors
All immunohistochemical analyses were performed in one
reference laboratory as described previously (Clahsen et al.,
1994a). Briefly, ER was measured biochemically using the
dextran-coated charcoal technique (positivity defined as
> 10 fmol mg-' protein); data were available in 387 cases.
PgR was detected using mPRI monoclonal antibody
(Transbio, Paris, France), c-erbB-2 using 3B5 monoclonal
antibody (Van de Vijver et al., 1988) (membrane staining
present= +), p53 using Do7 monoclonal antibody (Novo-
castra, Newcastle upon Tyne, UK) (staining score>4= +;
scoring range 0-7), and Ki-67 using MIB-1 (Immunotech,
Marseille, France) (>20% positive tumour cells= +).
Statistics
Statistical analyses were performed using SAS-software (SAS
Institute, Cary, NC, USA). Disease-free survival was defined
as the time interval between date of randomisation and date
of disease progression (including secondary primary cancer
and contralateral breast cancers) or death, whichever came
first. Locoregional recurrence was defined as a recurrence in
the homolateral breast or in homolateral regional lymph
nodes. Contralateral breast cancer was considered as a
secondary primary cancer and supraclavicular lymph node
metastases were evaluated as being distant metasases.
Differences in distribution of tumour parameters among
groups of patient characteristics were tested for using the chi-
square test. For analysis of the prognostic value of Bcl-2
expression on disease-free and overall survival, patients were
divided into two groups with low (0,1,2) or moderate to high
expression (3,4,5,6). Survival curves were estimated using the
Kaplan-Meier technique (Kaplan and Meier, 1958). Differ-
ences in the duration of survival were compared using a two-
sided log-rank test (Mantel, 1966). The proportional hazards
regression model (Cox, 1972) was used for multivariate
analysis. All P-values reported are two-sided.
Results
Expression of Bct-2 in normal breast tissue and apocrine
metaplasia
Within breast tissue of premenopausal women, pronounced
differences in Bcl-2 staining intensity were observed between
lobular ducts and intralobular ducts. In most cases
intralobular ducts stained strongly positive for Bcl-2 (Figure
la). Lobular ducts showed remarkable variability in staining
intensity between different breasts and even different lobules
within the same breast (Figure lb). On a cellular level this
heterogeneity in Bcl-2 expression was even more pronounced:
Figure lc shows an example of cells with strong cytoplasmic
staining scattered among cells that are very weakly stained.
Intralobular ducts generally showed strong, homogeneous
expression of Bcl-2. Luminal epithelial cells typically
expressed higher levels of Bcl-2 than myoepithelial cells, but
in some cases this expression pattern appeared to be reversed.
Apocrine metaplastic epithelium was observed in ten sections
and stained invariably negative for Bcl-2 (Figure ld). In
general, Bcl-2 immunoreactivity in breast epithelial cells
showed granular staining of the cytoplasm, suggestive of
localisation to cellular organelles, and strong perinuclear
staining. This is in line with previous publications on Bcl-2
localisation (De Jong et al., 1994).
Expression ofBct-2 in invasive carcinoma
Table I defines the full scoring system for the level of Bcl-2
staining. Staining intensity (SI) was scored negative (0),
weakly positive (1), moderately positive (2), or strongly
positive (3). Significant intratumour heterogeneity for Bcl-2
staining was observed in almost 30% of the cases. In most of
these cases all tumour cells were Bcl-2 positive, albeit withBcl-2 expression in breast cancer
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markedly varying intensity, whereas only a few 'hetero-
geneous' tumours contained a fraction of. tumour cells
virtually negative for Bcl-2. For this reason, it was decided
not to try to count the number of Bcl-2 'positive' tumour
cells. Instead, the fraction (F) of tumour cells showing the
most intense staining was estimated to be 0-25% (0), 25-
75% (1) or 75-100% (2). As depicted in Table I, tumours
were grouped into separate categories, not by addition or
multiplication of the two scores, but by classifying them
according to the fraction of cells showing the most intense
staining. Thus, tumours that had the same staining intensity
(SI), but also contained a significant number of tumour cells
with less staining (score F=0 or F = 1) were grouped
together. This scoring system resulted in Bcl-2 scores ranging
from 0 to 6. Lymphocytes always stained positive and served
as internal positive control. Of 441 cases stained intially, 18
could not be interpreted. Out of the remaining cases, 9.2% of
the tumours was completely negative (0), 17.2% weakly
(1+2), 41.6% moderately (3+4) and 31.9% strongly positive
(5 +6) for Bcl-2. An example of strong homogeneously
stained invasive ductal carcinoma is shown in Figure le.
Figure lf shows a typical example of intratumour hetero-
geneity; in this case the Bcl-2 staining pattern indicates the
existence of different cell clones with a marked difference in
Bcl-2 expression. In most cases, cellular heterogeneity
resembled staining patterns observed in lobular ducts,
varying from strongly positive to virtually negative (Figure
lg). Many tumours showed homogeneously weak staining of
the carcinoma cells (Figure lh). An example of a tumour
without immunoreactivity for Bcl-2 is shown in Figure li.
b
Figure 1 Immunohistochemical detection of Bcl-2 in normal and malignant breast epithelium. Paraffin-embedded tissue sections
were stained for Bcl-2 using clone 124 monoclonal antibodies. (a) Intralobular duct staining strongly positive for Bcl-2. (b)
Variations in Bcl-2 staining intensity between two different lobules within the same breast. (c) Heterogeneity of Bcl-2 expression on
a cellular level. Luminal epithelial cells staining strongly positive for Bcl-2 scattered among cells that stain weakly positive. (d)
Apocrine metaplasia staining negative for Bcl-2. Note that myoepithelial cells stain positive for Bcl-2. (e) Invasive breast carcinoma
showing strong, homogeneous staining for Bcl-2. (f) Invasive breast carcinoma showing marked intratumour heterogeneity for Bcl-2
expression. (g) Intratumour heterogeneity for Bcl-2 expression at a cell-to-cell level. (h) Invasive breast carcinoma showing
homogeneously weak staining for Bcl-2, note that intralobular ducts stain strongly positive. (i) Invasive carcinoma staining negative
for Bcl-2. Note that infiltrating lymphocytes stain strongly positive for Bcl-2.
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IExpression ofBcl-2 in components of ductal carcinoma in situ
(DCIS)
Staining intensity of DCIS present in the sections was scored
relative to that of the accompanying infiltrating component
(weaker, equal or stronger). A total of 64% of the
carcinomas contained a component of DCIS. Staining
intensity of the DCIS component for Bcl-2 was similar to
the invasive tumour cells in 79% of the cases (data not
shown). Of Bcl-2 negative carcinomas, 38% contained a
DCIS component and in 80% of the cases this DCIS
component was also negative for Bcl-2 staining.
Correlation of Bcl-2 expression with prognostic factors
The results of correlations between Bcl-2 content, various
prognostic factors and disease-free survival (DFS) and overall
survival (OS) are summarised in Figures 2 and 3 respectively.
A positive correlation was found between Bcl-2 expression
and low tumour grade (P<0.001) (Figure2a) and ER
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Table I Expression of Bcl-2 in invasive breast carcinoma
SI F Bcl-2 score Frequency Percentage
0 2 0 39 9.2
1 0 and I 1 20 4.7
1 2 2 53 12.5
2 0 and 1 3 39 9.2
2 2 4 137 32.4
3 Oand 1 5 61 14.4
3 2 6 74 17.5
Missing 18
Total 441 100.0
SI, staining intensity, range of scores 0-3; F, fraction of positive
tumour cells, fraction of cells in each category: 0-25% = 0, 25-
75% = 1, 75-100% = 2. Tumours were grouped into separate
categories, not by addition or multiplication of the two scores, but
by classifying them according to the fraction ofcells showing the most
intense staining. Tumours that had the same (SI), but also contained a
significant number of tumour cells with less intense staining (score
F = 0 or F = 1)were grouped together. This scoring system resulted in
Bcl-2 scores ranging from 0 to 6.
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Figure 2 Correlation between Bcl-2 expression and established prognostic factors. Shown are the correlations between Bcl-2
expression and: (a) tumour grade (Bloom-Richardson), (b) tumour size (Tl and T2), (c) oestrogen receptor status (determined by
ligand-binding assay; positivity defined as > 10fmolmg-' protein). Correlations between Bcl-2 expression and oestrogen and
progesterone receptor status assessed by immunohistochemistry yielded similar results (data not shown), (d) p53 status (staining
score >4= +; score range 0-7), (e) Ki-67 index (>20% positive tumour cells=positive) and (f) c-ErbB-2 expression.
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positivity (P<0.001) (Figure2c) and PgR positivity
(P<0.001) (data not shown). All tubular carcinomas (14/
14) expressed high levels of Bcl-2 as well as most mucinous
carcinomas (five out of six) and lobular carcinomas (26/32).
Medullary and atypical medullary carcinomas were predomi-
nantly negative (5/22) or weakly positive (12/22) for Bcl-2
staining (Table II).
Bcl-2 was negatively correlated with large tumour size
(P=0.006) (Figure 2b), p53 (P<0.001) (Figure 2d) and c-
erbB2 positivity (P<0.001) (Figure 2f), high Ki-67 index
(P<0.001) (Figure 2e) and high mitotic index (P<0.001)
(data not shown). No correlation was found with patient age.
Bcl-2 expression and DFS and OS
For statistical analysis of the prognostic value of Bcl-2
expression for DFS and OS, best separation of survival
curves was obtained when patients were divided into two
groups: undetectable or low expression (0-2) and moderate
to high expression (3-6) of Bcl-2. Patients with tumours
Table II Correlation between tumour histology and Bcl-2 expres-
sion
Bcl-2 negative Bcl-2 moderate
+ loWa (%) + higha (%)
Invasive ductal carcinoma (IDC) 82 (26.8) 224 (73.2)
Invasive lobular carcinoma (ILC) 6 (18.8) 26 (81.2)
IDC + ILC 6 (14.0) 37 (86.0)
Mucinous carcinoma 1 (16.7) 5 (83.3)
Tubular carcinoma 0 (0) 14 (100)
(Atypical) medullary carcinomab 17 (77.3) 5 (22.7)
aBcl-2 negative + low. Bcl-2 score is 0-2; Bcl-2 moderate + high:
Bcl-2 score is 3-6. For each tumour type the absolute number of
tumours in each category in depicted, whereas the percentage of
tumours in each category is shown in parentheses. bMedullary
carcinoma +atypical medullary carcinoma.
expressing high levels of Bcl-2 (overall score 3-6) had a
significantly better DFS (P=0.004) (Figure 3a) and OS
(P= 0.009) (Figure 3b) in the univariate analysis. However,
when tested in a multivariate model no significant correlation
was found with DFS or OS (data not shown).
Patients randomised to receive perioperative chemotherapy
had a significantly longer 4 year DFS than patients in the
control group (HR=0.60, 95% CI 0.40-0.91, P=0.02).
There was a trend for an effect of chemotherapy on DFS
both for patients with tumours with absent or low (Figure 3c
and Table III) and moderate or high (Figure 3d and Table
III) Bcl-2 expression. As can be seen, the response to
adjuvant chemotherapy is similar for Bcl-2-negative and
Bcl-2-positive tumours, indicating that Bcl-2 does not predict
response to perioperative chemotherapy in premenopausal,
lymph node-negative patients. Similarly, when all patients
with p53-positive tumours were omitted from the analysis,
Bcl-2 did not seem to predict response to chemotherapy (data
not shown).
Discussion
Adjuvant chemotherapy has been demonstrated to prolong
survival in lymph node-negative breast cancer patients (Early
Breast Cancer Trialists' Collaborative Group, 1992). How-
ever, the treatment effect is relatively small and selective use
of chemotherapy will be necessary to maximise the benefit to
individual patients. Thus, an important clinical problem is the
selection of those lymph node-negative patients that will
benefit from adjuvant chemotherapy. At present, no useful
biological markers able to predict response to chemotherapy
are available. In this study, we assessed relationships between
Bcl-2 expression and patient survival, response to adjuvant
chemotherapy and a number of clinicopathological para-
meters in a series of441 premenopausal, node-negative breast
cancer patients.
a
Disease-free survival
P= 0.004
- Low Bcl-2 score (0-2) (n = 112)
- High Bcl-2 score (3-6) (n = 311)
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P= 0.009
- Low Bc1-2 score (0-2) (n = 112)
- High Bcl-2 score (3-6) (n = 311)
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1 2 3 4 5 6 7 7
Time (years)
Figure 3 Bcl-2 protein expression as a prognostic factor for DFS and OS in node-negative premenopausal breast cancer patients.
Correlations between Bcl-2 expression and (a) DFS and (b) OS. Effect of perioperative chemotherapy on DFS in patients with
tumours expressing (c) undetectable or low and (d) moderate or high levels of Bcl-2.
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Table II Four year DFS and HRs for treatment effect by Bcl-2 score
Four-year DFS %
N/O (95% CI) HR (95% CI) P-value
Low Bcl-2 score (0-2)
Control 52/18 67.6 (54.4-80.8) 1.0
PeCT 60/14 79.5 (69.1-90.0) 0.55 (0.27-1.12) 0.09
High Bcl-2 score (3-6)
Control 150/31 81.0 (74.2-87.8) 1.0
PeCT 161/21 87.0 (81.0-93.0) 0.61 (0.35-1.06) 0.07
N, total number ofpatients; 0, number ofevents, DFS, disease-free survival; HR, hazard ratio; CI,
confidence interval; PeCT, perioperative chemotherapy.
Bcl-2 has been reported to be frequently expressed in
breast cancer and to be associated with favourable
clinicopathological parameters and favourable prognosis in
node-negative and node-positive breast cancers (Silvestrini et
al., 1994; Joensuu et al., 1994). In women with node-positive
breast cancer, Bcl-2 positivity was associated with favourable
outcome in patients treated with adjuvant chemotherapy and/
or hormone therapy (Gasparini et al., 1995; Gee et al., 1994;
Hellemans et al., 1995). However, because all patients in
these studies received adjuvant therapy, it was not possible to
determine whether high expression of Bcl-2 truly predicted
responsiveness or if it was merely a marker of good
prognosis.
In the present study, analysis of patient survival data
demonstrated that premenopausal, node-negative breast
cancer patients with tumours expressing moderate to high
levels of Bcl-2 had a significantly longer DFS and OS (Figure
3a and 3b). However, in multivariate analysis Bcl-2 was not
found to be an independent prognostic factor, a finding
similar to that recently reported by Silvestrini et al. (1994)
and Joensuu et al. (1994). Hellemans et al. (1995) did not
observe a significant association between Bcl-2 and DFS or
OS in 124 lymph node-negative breast cancer patients who
did not receive adjuvant treatment.
Response to perioperative chemotherapy did not differ
significantly among patients whose tumours expressed either
undetectable to low or moderate to high levels of Bcl-2
(Figure 3c and 3d and Table III). These findings demonstrate
that although moderate to high expression of Bcl-2 is a
marker of favourable prognosis, Bcl-2 does not seem to
predict response to adjuvant chemotherapy in this series of
premenopausal, node-negative breast cancer patients. One
may argue that only one cycle of perioperative chemotherapy
cannot be considered an adequate treatment to assess the
relationship between Bcl-2 expression and response to
chemotherapy. However, the adjuvant chemotherapy regi-
men used in this trial can be described as a fairly intensive
course of polychemotherapy. This regimen of perioperative
chemotherapy resulted in a relatively small, but significant
increase in DFS and OS in the group of premenopausal,
lymph node-negative patients. Moreover, the benefit obtained
with the single course of FAC used in this trial, was similar
to results obtained with more prolonged administration of
adjuvant chemotherapy in lymph node-negative patients
(Early Breast Cancer Trialists' Collaborative Group, 1992).
In this respect, it seems unlikely that the failure of Bcl-2 to
predict response to chemotherapy in node-negative patients
can be contributed to the treatment regimen used in this trial.
In addition, it is important to note that the 'perioperative'
chemotherapy, was given within 24 h after surgery and thus
did not affect the expression level of Bcl-2.
An important finding, with respect to the association of
high expression of Bcl-2 with improved survival, was the
strong correlations observed between Bcl-2 expression and a
number of important clinicopathological parameters (Figure
2a-f). High expression of Bcl-2 was positively correlated
with well-differentiated tumours and low tumour grade and
with ER and PgR positivity. High Bcl-2 expression was
negatively correlated with p53 and c-erbB-2 positivity, with
high MIB-1 (Ki-67) index and high mitotic index and with
large tumour size. Thus, expression of Bcl-2 was associated
with the presence of a number of classical prognostic factors
known to predict a lower risk of relapse, providing a likely
explanation for the improved survival of patients with
tumours expressing high levels of Bcl-2.
An important finding, with regard to the failure of Bcl-2 to
predict responsiveness, seemed to be the strong negative
correlation between Bcl-2 expression and p53 protein
accumulation, in concordance with recent reports by other
groups (Leek et al., 1994; Silvestrini et al., 1994; Joensuu et
al., 1994; Gasparini et al., 1995). Recently, evidence has been
obtained that wild-type as well as most mutant p53 proteins
can down-regulate Bcl-2 expression in vitro and in vivo
(Haldar et al., 1994; Selvakumaran et al., 1994; Miyashita et
al., 1994). Mutations in the p53 tumour-suppressor gene are a
marker of poor prognosis in node-negative breast cancer
(Isola et al., 1992) and experimental data have demonstrated
increased resistance to doxorubicin and gamma irradiation in
tumours lacking functional p53 (Lowe et al., 1994). We also
evaluated the predictive value of Bcl-2 expression on
responsiveness in the subgroup of patients with p53-negative
tumours. Again, Bcl-2 did not seem to predict response to
chemotherapy. Thus, the failure of Bcl-2 to predict response
to chemotherapy is not the result of the relatively high
percentage of p53-positive tumours in the group of patients
with negative to low expression of Bcl-2.
It should be realised that bcl-2 is only one member of an
expanding family of genes involved in cell death regulation,
including bcl-X (Boise et al., 1993), mcl-i (Reynolds et al.,
1994), al (Lin et al., 1993), bax (Oltvai et al., 1993), bad
(Yang et al., 1995) and bak (Kiefer et al., 1995), that have not
yet been studied in human cancer. The proteins encoded by
these genes can bind to each other, forming homodimers and
heterodimers, as well as physically interact with a number of
other proteins. Co-expression of these proteins can either
decrease or increase the cellular threshold for induction of
apoptosis set by Bcl-2, and may explain the failure of Bcl-2 to
predict responsiveness in this series of patients.
The observation that Bcl-2 is preferentially expressed in
well-differentiated tumours is in line with data on Bcl-2
expression in other types of solid tumours (e.g. non-small cell
lung cancer and thyroid carcinoma) (Pezzella et al., 1993;
Pilotti et al., 1994). In thyroid carcinoma, bcl-2 appeared to
be under the control of differentiation-related transcription
factors (Civitareale et al., 1989). The data presented in this
study suggest the presence of a similar differentiation-
dependent regulation of bcl-2 in breast epithelium. This
hypothesis is supported by the strong positive correlations
found between high Bcl-2 expression and ER postivity. Of
interest, in this context, is that all observed cases of apocrine
metaplasia were found to be completely negative for both
Bcl-2 (Figure Id) and ER (data not shown). These findings
indicate that in breast epithelium Bcl-2 expression is under
the control of oestrogen. Data on Bcl-2 expression in normal
breast tissue and endometrium during the menstrual cycle
support the hypothesis that bcl-2 gene expression is
hormonally regulated (Sabourin et al., 1994; Gompel et al.,
1994).Bd-2 ixprsm rnIcer
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A DCIS component was present in 65.5% ofthe cases and
mostly showed a similar Bcl-2 expression as the invasive
component (only 20.5% was judged to have a stronger or
weaker staining intensity), suggesting that clonal variations in
Bcl-2 expression are a relatively early event in tumour
progression.
In conclusion, this study confirms that Bcl-2 is a strong,
but not an independent marker of favourable prognosis and
demonstrates that it has little predictive value for response to
a single course ofpolychemotherapy in premenopausal, node-
negative breast cancer patients.
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